BioScrip inks cancer drug deal with Access

NEW YORK Specialty pharmacy provider BioScrip and drug maker Access Pharmaceuticals have signed a distribution agreement for a drug used to treat cancer patients, Access said Tuesday.

Under the agreement, BioScrip will distribute MuGard, an oral wound rinse used to manage oral mucositis, a side effect of radiotherapy and chemotherapy.

“BioScrip is proud to have been selected by Access to be its exclusive distribution and service partner for MuGard,” BioScrip SVP trade relations and business development Scott Friedman said. “Our vast clinical, sales and operational specialty pharmacy assets, combined with our deep oncology experience, put us in a unique position to provide services to the patient, manufacturer, provider and payer communities.”